Ruxolitinib, iyo inozivikanwawo se ruxolitinib muChina, ndeimwe ye "mishonga mitsva" yakave yakanyorwa zvakanyanya mumakiriniki mazano ekurapa zvirwere zvehematological mumakore achangopfuura, uye yakaratidza kubudirira kunovimbisa muzvirwere zvemyeloproliferative.
Mushonga wakanangwa Jakavi ruxolitinib unokwanisa kuvharisa kuvhurwa kweiyo yese JAK-STAT chiteshi uye kuderedza iyo yakasarudzika inosimudzira chiratidzo chechiteshi, nekudaro kuwana kushanda. Inogona zvakare kushandiswa pakurapa kwemhando dzakasiyana dzezvirwere, uye kune JAK1 saiti abnormalities.
Ruxolitinibinonzi kinase inhibitor inoratidzirwa kurapwa kwevarwere vane myelofibrosis yepakati kana yakakwirira, kusanganisira primary myelofibrosis, post-geniculocytosis myelofibrosis, uye post-primary thrombocythemia myelofibrosis.
Chidzidzo chekiriniki chakafanana (n = 219) varwere vane hutachiona hwepakati-panjodzi-2 kana yepamusoro-ngozi yekutanga MF, varwere vane MF mushure mechokwadi erythroblastosis, kana varwere vane MF mushure mekutanga thrombocytosis kumapoka maviri, mumwe achigamuchira oral ruxolitinib 15 kusvika 20 mgbid. (n=146) uye mumwe achiwana mushonga wakanaka wekudzora (n=73). Mhedziso yekutanga uye yakakosha yechipiri yekudzidza yaive yezana yevarwere vane ≥35% kuderedzwa kwespleen volume (yakaongororwa nemagnetic resonance imaging kana computed tomography) pavhiki 48 uye 24, maererano. Zvigumisiro zvakaratidza kuti chikamu chevarwere vane zvinopfuura 35% kuderedza spleen volume kubva pakutanga kwevhiki 24 yaiva 31.9% muboka rekurapa kana ichienzaniswa ne0% muboka rinodzora (P <0.0001); uye chikamu chevarwere vane zvinopfuura 35% kuderedza spleen volume kubva pakutanga pavhiki 48 yaiva 28.5% muboka rekurapa kana ichienzaniswa ne0% muboka rinodzora (P <0.0001). Mukuwedzera, ruxolitinib yakaderedzawo zviratidzo zvakazara uye yakanyatsovandudza hupenyu hwevarwere. Zvichienderana nemhedzisiro yemakiriniki maviri aya miedzo,ruxolitinibwakava mushonga wekutanga kubvumidzwa neUS FDA kurapwa kwevarwere vane MF.